Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors.
Ujvari D, Malyukova A, Zovko A, Yektaei-Karin E, Madapura HS, Keszei M, Nagy N, Lotfi K, Björn N, Wallvik J, Stenke L, Salamon D. Ujvari D, et al. Among authors: stenke l. Oncoimmunology. 2022 Aug 12;11(1):2109861. doi: 10.1080/2162402X.2022.2109861. eCollection 2022. Oncoimmunology. 2022. PMID: 35979386 Free PMC article.
Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
Richter J, Söderlund S, Lübking A, Dreimane A, Lotfi K, Markevärn B, Själander A, Saussele S, Olsson-Strömberg U, Stenke L. Richter J, et al. Among authors: stenke l. J Clin Oncol. 2014 Sep 1;32(25):2821-3. doi: 10.1200/JCO.2014.55.6910. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071107 No abstract available.
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group. Hjorth-Hansen H, et al. Among authors: stenke l. Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13. Eur J Haematol. 2015. PMID: 25082346 Free PMC article. Clinical Trial.
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
Christiansson L, Söderlund S, Mangsbo S, Hjorth-Hansen H, Höglund M, Markevärn B, Richter J, Stenke L, Mustjoki S, Loskog A, Olsson-Strömberg U. Christiansson L, et al. Among authors: stenke l. Mol Cancer Ther. 2015 May;14(5):1181-91. doi: 10.1158/1535-7163.MCT-14-0849. Epub 2015 Mar 11. Mol Cancer Ther. 2015. PMID: 25761894
132 results